Expert Perspectives on Therapeutic Advances to Improve Clinical Outcomes of Veterans With NSCLC

Expert Perspectives on Therapeutic Advances to Improve Clinical Outcomes of Veterans With NSCLC

Thursday, February 14, 2019 in San Antonio, Texas
Live Meeting -- Audie L. Murphy Memorial VA Hospital, 8:00 AM CT
Pathology Conference Room


Program Overview

Clinical Application of New Data and Therapies

  • Case 1: An elderly former smoker with squamous histology: choice of first-line chemotherapy and therapy after progression on platinum-based chemotherapy; PD-L1 expression unknown
  • Case 2: Patient with newly diagnosed stage IV lung adenocarcinoma; high percentage of PD-L1–positive cells
  • Case 3: A former light smoker with newly diagnosed adenocarcinoma of high burden
  • Case 4: A former light smoker with adenocarcinoma of high burden and progression on previous EGFR TKI therapy; rebiopsy positive for T790M mutation
  • Case 5: Patient with locally advanced unresectable stage III NSCLC without progression

Future Directions in NSCLC Care

Question and Answer Session, Closing Remarks


Jonathan Dowell, MD

Associate Professor of Internal Medicine 
Department of Hematology/Oncology
University of Texas Southwestern Medical Center
Chief, Section of Hematology/Oncology
Dallas VA Medical Center
Dallas, Texas

Program Overview
Gain expert guidance on the latest treatment of veterans with non-small-cell lung cancer in this 1-hour interactive meeting, with an opportunity to discuss your challenging cases with the experts. Afterward, an associated downloadable slideset will be available on the CCO Web site to enhance the information presented at the live meetings.

Goal Statement
The goal of this activity is to improve participants’ competence in treating patients with non-small-cell lung cancer.

Target Audience
This program is intended for physicians, registered nurses, and other healthcare providers who care for veterans with lung cancer.

Learning Objectives

  • Optimally test for EGFR, ALK, ROS-1, and BRAF aberrations in patients with NSCLC
  • Integrate the latest guidelines and clinical data to the treatment of patients with advanced-stage NSCLC based on tumor histology
  • Plan treatment strategies for patients with NSCLC based on the molecular profile of the tumor as well as available data, treatment guidelines, and expert recommendations
  • Identify patients with stage III or metastatic NSCLC who may benefit from immune checkpoint inhibitor therapy
  • Manage treatment-related adverse events in patients with advanced NSCLC


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

Credit Designation
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hour.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.